These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 8021912)

  • 61. [Ezetimibe].
    Taéron C
    Rev Infirm; 2005 Mar; (109):43-4. PubMed ID: 15853083
    [No Abstract]   [Full Text] [Related]  

  • 62. Ezetimibe (Schering-Plough).
    Meng CQ
    Curr Opin Investig Drugs; 2001 Mar; 2(3):389-92. PubMed ID: 11575710
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The ACAT inhibitor HL-004 inhibits cholesterol absorption and lowers serum cholesterol in rats.
    Asami Y; Kondo Y; Murakami S; Araki H; Tsuchida K; Higuchi S
    Gen Pharmacol; 1998 Oct; 31(4):593-6. PubMed ID: 9792221
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Inhibitors of acyl-Coa:cholesterol acyltransferase. 4. A novel series of urea ACAT inhibitors as potential hypocholesterolemic agents.
    Trivedi BK; Holmes A; Stoeber TL; Blankley CJ; Roark WH; Picard JA; Shaw MK; Essenburg AD; Stanfield RL; Krause BR
    J Med Chem; 1993 Oct; 36(22):3300-7. PubMed ID: 8230120
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Genetic background of the efficacy of cholesterol absorption. The role of Niemann-Pick C1-like 1 receptor and its genetic variations in lipid metabolism].
    Harangi M; Balogh I; Harangi J; Paragh G
    Orv Hetil; 2010 Aug; 151(34):1376-83. PubMed ID: 20705552
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Saucerneol B derivatives as human acyl-CoA: cholesterol acyltransferase inhibitors.
    Jeong TS; Kim KS; Yu H; Kim MJ; Cho KH; Choi YK; Kim HC; Park HY; Lee WS
    Bioorg Med Chem Lett; 2005 Jan; 15(2):385-8. PubMed ID: 15603959
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Making sense of ENHANCE: ezetimibe (Zetia) lowers LDL cholesterol but doesn't decrease carotid intima-media thickness.
    Smith D
    Mt Sinai J Med; 2008; 75(2):143-7. PubMed ID: 18500716
    [No Abstract]   [Full Text] [Related]  

  • 68. Potential antiatherosclerotic agents. 5. An acyl-CoA:cholesterol O-acyltransferase inhibitor with hypocholesterolemic activity.
    DeVries VG; Schaffer SA; Largis EE; Dutia MD; Wang CH; Bloom JD; Katocs AS
    J Med Chem; 1986 Jul; 29(7):1131-3. PubMed ID: 3100794
    [No Abstract]   [Full Text] [Related]  

  • 69. Ezetimibe, a selective inhibitor of the transport of cholesterol.
    Miura S; Saku K
    Intern Med; 2008; 47(13):1165-70. PubMed ID: 18591835
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Syntheses and pharmacological activities of novel optically active inhibitors of acyl-CoA: cholesterol O-acyltransferase: EAB-309 ((R)-N-2-(1,3-benzodioxol-4-yl)heptyl-N'-2,6-diisopropylphenylurea) and its enantiomer.
    Sekiya T; Inoue S; Shirasaka T; Miyajima C; Okushima H; Suzuki K; Kawai M; Mitsuka M; Umezu K
    Chem Pharm Bull (Tokyo); 1994 Mar; 42(3):586-91. PubMed ID: 8004704
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese hyperinsulinemic hamsters.
    van Heek M; Austin TM; Farley C; Cook JA; Tetzloff GG; Davis HR
    Diabetes; 2001 Jun; 50(6):1330-5. PubMed ID: 11375333
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cluster significance analysis of the anticholesterolemic action of acyl-CoA cholesterol: acyltransferase inhibitors.
    Ordorica Vargas MA; Velázquez Monroy Mde L; Ordorica Vargas JG; Lehmann Feitler PA
    Proc West Pharmacol Soc; 2002; 45():79-81. PubMed ID: 12434537
    [No Abstract]   [Full Text] [Related]  

  • 73. Discovery, synthesis and evaluation of novel cholesterol absorption inhibitors.
    Zhu X; Ji J; Huang D; Zhu Y; Tang C; Yang X; Qian H; Huang W
    Chem Biol Drug Des; 2012 Sep; 80(3):426-33. PubMed ID: 22642541
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Ezetimibe, an inhibitor of intestinal cholesterol absorption, decreases serum level of malondialdehyde-modified low-density lipoprotein in patients with hypercholesterolemia.
    Ueda S; Miyake I; Takata K; Shimizu N; Shirotani K; Ishida S; Yonemitsu K; Maeyama T; Saito F; Saito H; Yamagishi S
    Int J Cardiol; 2011 Feb; 146(3):420-1. PubMed ID: 21106263
    [No Abstract]   [Full Text] [Related]  

  • 75. [Ezetimib. A new cholesterol absorption inhibitor].
    Heinzl S
    Med Monatsschr Pharm; 2002 Jul; 25(7):229-32. PubMed ID: 12148235
    [No Abstract]   [Full Text] [Related]  

  • 76. Synthesis and evaluation of novel amide amino-β-lactam derivatives as cholesterol absorption inhibitors.
    Dražić T; Sachdev V; Leopold C; Patankar JV; Malnar M; Hećimović S; Levak-Frank S; Habuš I; Kratky D
    Bioorg Med Chem; 2015 May; 23(10):2353-9. PubMed ID: 25882530
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Selective inhibition of mammalian lanosterol 14 alpha-demethylase: a possible strategy for cholesterol lowering.
    Walker KA; Kertesz DJ; Rotstein DM; Swinney DC; Berry PW; So OY; Webb AS; Watson DM; Mak AY; Burton PM
    J Med Chem; 1993 Jul; 36(15):2235-7. PubMed ID: 8340925
    [No Abstract]   [Full Text] [Related]  

  • 78. Hypocholesterolemic activity of hesperetin derivatives.
    Jeong TS; Kim EE; Lee CH; Oh JH; Moon SS; Lee WS; Oh GT; Lee S; Bok SH
    Bioorg Med Chem Lett; 2003 Aug; 13(16):2663-5. PubMed ID: 12873489
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Potential antiatherosclerotic agents. 6. Hypocholesterolemic trisubstituted urea analogues.
    DeVries VG; Bloom JD; Dutia MD; Katocs AS; Largis EE
    J Med Chem; 1989 Oct; 32(10):2318-25. PubMed ID: 2795605
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Pyripyropenes, highly potent inhibitors of acyl-CoA:cholesterol acyltransferase produced by Aspergillus fumigatus.
    Omura S; Tomoda H; Kim YK; Nishida H
    J Antibiot (Tokyo); 1993 Jul; 46(7):1168-9. PubMed ID: 8360113
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.